Phenobarbitone
Evidence-based neurology checklist on phenobarbitone: Mode of action Phenobarbitone facilitates GABA-mediated inhibition It reduces glutamate mediated excitatory neurotransmission It may reduce calcium channel mediated reduction of neurotransmitter release Indications Dosing Teratogenicity: risk…
Mode of action
- Phenobarbitone facilitates GABA-mediated inhibition
- It reduces glutamate mediated excitatory neurotransmission
- It may reduce calcium channel mediated reduction of neurotransmitter release
Indications
Dosing
Teratogenicity: risk of major congenital malformations (MCMs)
Teratogenicity: types of major congenital malformations (MCMs)
Neuropsychiatric side effects
Systemic side effects
Long-term monitoring: 2-5 yearly
Drugs that reduce the level of Phenobarbitone
References
- Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T 2010; 35:392-415.
- Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004; 45:1141-1149.
- Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia 2012; 53(Suppl 8):40-46.
- Elafros MA, Bui E, Birbeck GL. Medication side effects among people with epilepsy taking phenobarbital in Zambia. Epilepsy Res 2014; 108:1680-1684.
- Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia 2012; (53 Suppl 8):26-39.
- And 5 more. Subscribe to see the full list
